Apixaban appeal

The Court of Appeal (Arnold, Nugee, Warby LLJ) handed down the appeal judgment in Sandoz, Teva v BMS, upholding Meade J’s decision at first instance to revoke the patent which concerns the blockbuster anticoagulant drug apixaban. The decision is the first in the UK to address the law of plausibility following the written decision of the Enlarged Board of Appeal in G2/21 Sumitomo.

The Court of Appeal’s judgment is available here.

Sandoz was represented by Michael Tappin KC leading Stuart Baran and Alice Hart, instructed by Bristows. Teva was represented by Justin Turner KC leading Thomas Lunt, instructed by Pinsent Masons.


Posted On Category News